应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
DNLI Denali Therapeutics Inc.
未开盘 10-23 16:00:00 EDT
18.41
-0.25
-1.34%
盘后
18.49
+0.08
+0.43%
19:30 EDT
最高
18.50
最低
18.01
成交量
100.56万
今开
18.49
昨收
18.66
日振幅
2.65%
总市值
29.43亿
流通市值
27.81亿
总股本
1.60亿
成交额
1,846万
换手率
0.67%
流通股本
1.51亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
财报前瞻|Denali Therapeutics Inc.本季度营收预计增125.86%,机构观点偏多
财报Agent · 07-30
财报前瞻|Denali Therapeutics Inc.本季度营收预计增125.86%,机构观点偏多
渤健与Denali Therapeutics公布早期帕金森病药物Biib122(Dnl151)IIb期Luma研究进展
美股速递 · 05-22
渤健与Denali Therapeutics公布早期帕金森病药物Biib122(Dnl151)IIb期Luma研究进展
异动解读 | 受百健阿尔茨海默病疗法进展带动,Denali Therapeutics盘前大涨7.98%
异动解读 · 05-14
异动解读 | 受百健阿尔茨海默病疗法进展带动,Denali Therapeutics盘前大涨7.98%
B of A Securities:维持Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由30.00美元调整至28.00美元。
金融界 · 2025-03-11
B of A Securities:维持Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由30.00美元调整至28.00美元。
Denali Therapeutics Inc.盘中异动 早盘急速跳水5.03%
市场透视 · 2025-03-10
Denali Therapeutics Inc.盘中异动 早盘急速跳水5.03%
Denali Therapeutics Inc.2024财年实现净利润-4.23亿美元,同比减少191.72%
市场透视 · 2025-03-08
Denali Therapeutics Inc.2024财年实现净利润-4.23亿美元,同比减少191.72%
Denali Therapeutics Inc.盘中异动 早盘股价大跌5.55%报15.40美元
市场透视 · 2025-03-06
Denali Therapeutics Inc.盘中异动 早盘股价大跌5.55%报15.40美元
B. Riley Securities:重申Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由38.00美元调整至35.00美元。
金融界 · 2025-03-06
B. Riley Securities:重申Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由38.00美元调整至35.00美元。
奥本海默:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由50.00美元调整至42.00美元。
金融界 · 2025-03-04
奥本海默:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由50.00美元调整至42.00美元。
Denali Therapeutics Inc.盘中异动 快速下跌5.07%
市场透视 · 2025-03-04
Denali Therapeutics Inc.盘中异动 快速下跌5.07%
Denali Therapeutics(DNLI.US):2024年Q4财报实现营收0美元,前值为0美元,预期值为1258万美元;每股收益为-0.67美元,前值为-0.86美元,预期值为-0.91美元。
金融界 · 2025-02-28
Denali Therapeutics(DNLI.US):2024年Q4财报实现营收0美元,前值为0美元,预期值为1258万美元;每股收益为-0.67美元,前值为-0.86美元,预期值为-0.91美元。
Denali Therapeutics 2024年第四季度GAAP每股收益$(0.67),优于$(0.76)的预期
财报速递 · 2025-02-28
Denali Therapeutics 2024年第四季度GAAP每股收益$(0.67),优于$(0.76)的预期
Denali Therapeutics Inc.盘中异动 大幅下挫5.03%报19.63美元
市场透视 · 2025-02-26
Denali Therapeutics Inc.盘中异动 大幅下挫5.03%报19.63美元
Denali Therapeutics(DNLI.US)获德银首次覆盖,给予买入评级, 目标价31.00美元。
金融界 · 2025-02-12
Denali Therapeutics(DNLI.US)获德银首次覆盖,给予买入评级, 目标价31.00美元。
Denali Therapeutics Inc.盘中异动 急速下挫5.06%
市场透视 · 2025-02-11
Denali Therapeutics Inc.盘中异动 急速下挫5.06%
Denali Therapeutics Inc.盘中异动 快速上涨5.08%
市场透视 · 2025-02-04
Denali Therapeutics Inc.盘中异动 快速上涨5.08%
Denali Therapeutics Inc.盘中异动 股价大跌5.02%报22.13美元
市场透视 · 2025-02-04
Denali Therapeutics Inc.盘中异动 股价大跌5.02%报22.13美元
高盛:维持Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至40.00美元。
金融界 · 2025-01-28
高盛:维持Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至40.00美元。
Denali Therapeutics Inc.盘中异动 下午盘股价大涨5.02%
市场透视 · 2025-01-22
Denali Therapeutics Inc.盘中异动 下午盘股价大涨5.02%
Denali Therapeutics Inc.盘中异动 早盘快速拉升5.12%报19.70美元
市场透视 · 2025-01-15
Denali Therapeutics Inc.盘中异动 早盘快速拉升5.12%报19.70美元
加载更多
公司概况
公司名称:
Denali Therapeutics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Denali Therapeutics Inc.于2013年10月在特拉华州注册成立。他们的目标是发现和开发可以战胜神经退行性疾病的治疗药物。神经退化代表了他们那个时代最重要的未得到满足的医疗需求之一,比如阿尔茨海默病,帕金森病疾病,肌萎缩性侧索硬化症或ALS,以及其他神经退化性疾病。这些疾病对患者和社会的负担是巨大的。他们相信现在正是他们利用强有力和雄心勃勃的努力来打败神经退化的正确时机。他们相信,他们可以在一个很少成功的领域取得了成就,因为他们拥有丰富的成功经验、热忱的科学家和药物开发者团队,他们专注的科学战略,以及他们专有的血脑屏障(BBB)平台输送技术。他们正在开发广泛的神经退行性疾病靶向治疗候选药物组合,并且最近开始了他们的第一个临床试验。他们于2015年5月开始运营。
发行价格:
--
{"stockData":{"symbol":"DNLI","market":"US","secType":"STK","nameCN":"Denali Therapeutics Inc.","latestPrice":18.41,"timestamp":1792785600000,"preClose":18.66,"halted":0,"volume":1005558,"hourTrading":{"tag":"盘后","latestPrice":18.49,"preClose":18.41,"latestTime":"19:30 EDT","volume":185399,"amount":3413736.0347,"timestamp":1792798205149,"change":0.08,"changeRate":0.004345,"amplitude":0.01358},"delay":0,"changeRate":-0.01339764201500536,"floatShares":151072166,"shares":159847403,"eps":-2.835349,"marketStatus":"未开盘","change":-0.25,"latestTime":"10-23 16:00:00 EDT","open":18.49,"high":18.5,"low":18.005,"amount":18457852.708697997,"amplitude":0.026527,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.835349,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1512709200000,"exchange":"NASDAQ","adjPreClose":18.66,"preHourTrading":{"tag":"盘前","latestPrice":18.55,"preClose":18.66,"latestTime":"08:55 EDT","volume":816,"amount":15167.44896,"timestamp":1792760132723,"change":-0.11,"changeRate":-0.005895,"amplitude":0.133976},"postHourTrading":{"tag":"盘后","latestPrice":18.49,"preClose":18.41,"latestTime":"19:30 EDT","volume":185399,"amount":3413736.0347,"timestamp":1792798205149,"change":0.08,"changeRate":0.004345,"amplitude":0.01358},"volumeRatio":0.554742690908918,"impliedVol":0.6377,"impliedVolPercentile":0.5657},"requestUrl":"/m/hq/s/DNLI","defaultTab":"news","newsList":[{"id":"1120339189","title":"财报前瞻|Denali Therapeutics Inc.本季度营收预计增125.86%,机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1120339189","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120339189?lang=zh_cn&edition=full","pubTime":"2026-07-30 14:54","pubTimestamp":1785394454,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc.将于2026年08月06日美股盘后发布最新季度财报,市场关注Avlayah商业化与费用节奏对盈利路径的影响。市场一致预期显示,本季度Denali Therapeutics Inc.营收预计为1,461.31万美元,同比增125.86%;调整后每股收益预计为-0.66美元,同比改善8.71%。上一季度Denali Therapeutics Inc.营收为0.00美元,同比0.00%;毛利率未披露;归属于母公司股东的净利润为-1.28亿美元,同比未披露;净利率未披露;调整后每股收益为-0.69美元,同比改善11.54%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Denali Therapeutics Inc.本季度营收预计增125.86%,机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179602120","title":"渤健与Denali Therapeutics公布早期帕金森病药物Biib122(Dnl151)IIb期Luma研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1179602120","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179602120?lang=zh_cn&edition=full","pubTime":"2026-05-22 06:00","pubTimestamp":1779400816,"startTime":"0","endTime":"0","summary":"渤健公司(Biogen)与Denali Therapeutics Inc. 近日就双方共同研发的、针对早期帕金森病的在研药物Biib122(亦称Dnl151)的IIb期临床试验(Luma研究)提供了最新进展信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4535","IE00B894F039.SGD","BK4585","BK4139","DNLI","IE00B19Z9P08.USD","LU0889565916.HKD","BK4548","BK4588","BK4533","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4532","LU0109394709.USD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148388505","title":"异动解读 | 受百健阿尔茨海默病疗法进展带动,Denali Therapeutics盘前大涨7.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148388505","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148388505?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:37","pubTimestamp":1778758626,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc.(DNLI)今日盘前股价大幅上涨7.98%,引起了市场的广泛关注。消息面上,百健(BIIB)宣布计划将其用于治疗阿尔茨海默病的实验性药物diranersen推进至后期开发阶段,该疗法在中期试验中显示出减少tau蛋白堆积和改善患者认知功能的潜力。由于Denali Therapeutics同样在研发阿尔茨海默病疗法,市场预期该公司可能受益于整个行业研发进展带来的积极情绪,从而推动其股价上涨。这一事件凸显了市场对神经退行性疾病治疗领域创新进展的高度敏感,相关公司的股价波动往往受到同业研发动态的显著影响。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518082312","title":"B of A Securities:维持Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由30.00美元调整至28.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518082312","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518082312?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:02","pubTimestamp":1741626170,"startTime":"0","endTime":"0","summary":"B of A Securities:维持Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由30.00美元调整至28.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11010248641320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["DNLI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518385208","title":"Denali Therapeutics Inc.盘中异动 早盘急速跳水5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518385208","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518385208?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:47","pubTimestamp":1741614463,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时47分,Denali Therapeutics Inc.股票出现波动,股价快速下跌5.03%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.30%。其相关个股中,Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大,Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃,换手率分别为2636.55%、601.31%、91.59%,振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.,振幅分别为40.24%、28.59%、25.35%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214743abf30282&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214743abf30282&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","DNLI","LENZ","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517453968","title":"Denali Therapeutics Inc.2024财年实现净利润-4.23亿美元,同比减少191.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517453968","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517453968?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363252,"startTime":"0","endTime":"0","summary":"3月8日,Denali Therapeutics Inc.公布财报,公告显示公司2024财年净利润为-4.23亿美元,同比减少191.72%;其中营业收入为0.00美元,每股基本收益为-2.57美元。机构评级:截至2025年3月8日,当前有16家机构对Denali Therapeutics Inc.目标价做出预测,其中目标均价为36.94美元,其中最低目标价为24.00美元,最高目标价为80.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000228abed66a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000228abed66a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DNLI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517162354","title":"Denali Therapeutics Inc.盘中异动 早盘股价大跌5.55%报15.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162354","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517162354?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:33","pubTimestamp":1741271613,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时33分,Denali Therapeutics Inc.股票出现波动,股价急速跳水5.55%。截至发稿,该股报15.40美元/股,成交量3.5016万股,换手率0.02%,振幅2.67%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.60%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223333abeb784b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223333abeb784b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","LENZ","BK4548","BK4139","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517294201","title":"B. Riley Securities:重申Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由38.00美元调整至35.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517294201","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517294201?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:22","pubTimestamp":1741195338,"startTime":"0","endTime":"0","summary":"B. Riley Securities:重申Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由38.00美元调整至35.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06012248550715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["DNLI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516510756","title":"奥本海默:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由50.00美元调整至42.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516510756","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516510756?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:00","pubTimestamp":1741024838,"startTime":"0","endTime":"0","summary":"奥本海默:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由50.00美元调整至42.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04020048498822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516567096","title":"Denali Therapeutics Inc.盘中异动 快速下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516567096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516567096?lang=zh_cn&edition=full","pubTime":"2025-03-04 01:00","pubTimestamp":1741021227,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日01时00分,Denali Therapeutics Inc.股票出现异动,股价大幅跳水5.07%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.05%。其相关个股中,Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大,Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃,换手率分别为4043.54%、175.65%、144.19%,振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.,振幅分别为206.20%、119.50%、70.53%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304010027989a3215&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304010027989a3215&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","LENZ","DNLI","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514035432","title":"Denali Therapeutics(DNLI.US):2024年Q4财报实现营收0美元,前值为0美元,预期值为1258万美元;每股收益为-0.67美元,前值为-0.86美元,预期值为-0.91美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514035432","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514035432?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:08","pubTimestamp":1740697718,"startTime":"0","endTime":"0","summary":"Denali Therapeutics(DNLI.US):2024年Q4财报实现营收0美元,前值为0美元,预期值为1258万美元;每股收益为-0.67美元,前值为-0.86美元,预期值为-0.91美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28070848442546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164845017","title":"Denali Therapeutics 2024年第四季度GAAP每股收益$(0.67),优于$(0.76)的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1164845017","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164845017?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:38","pubTimestamp":1740692304,"startTime":"0","endTime":"0","summary":"Denali Therapeutics公布的季度每股亏损为$,比分析师一致预期的$高出11.84%。与去年同期的每股亏损$相比,这实现了22.09%的增长。以上内容来自Benzinga Earnings专栏,原文如下:Denali $Therapeutics$ reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 11.84 percent. This is a 22.09 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514197800","title":"Denali Therapeutics Inc.盘中异动 大幅下挫5.03%报19.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514197800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514197800?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:13","pubTimestamp":1740500033,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时13分,Denali Therapeutics Inc.股票出现异动,股价快速跳水5.03%。截至发稿,该股报19.63美元/股,成交量19.9454万股,换手率0.14%,振幅5.61%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.53%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001354a2539e7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001354a2539e7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DNLI","BK4535","LENZ","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510358965","title":"Denali Therapeutics(DNLI.US)获德银首次覆盖,给予买入评级, 目标价31.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510358965","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510358965?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:02","pubTimestamp":1739296955,"startTime":"0","endTime":"0","summary":"Denali Therapeutics(DNLI.US)获德银首次覆盖,给予买入评级, 目标价31.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12020248092616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["DNLI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510397860","title":"Denali Therapeutics Inc.盘中异动 急速下挫5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510397860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510397860?lang=zh_cn&edition=full","pubTime":"2025-02-11 00:53","pubTimestamp":1739206426,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日00时53分,Denali Therapeutics Inc.股票出现波动,股价快速下跌5.06%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.19%。其相关个股中,60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Biodexa Pharmaceuticals Plc、Dominari Holdings Inc.涨幅较大,Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃,换手率分别为2896.40%、1581.29%、1119.08%,振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Abpro Holdings Inc C/Wts 12/11/2029 、Ocean Biomedical, Inc.,振幅分别为99.86%、87.80%、85.48%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211005346961e1be4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211005346961e1be4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4535","DNLI","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508468089","title":"Denali Therapeutics Inc.盘中异动 快速上涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508468089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508468089?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:11","pubTimestamp":1738681867,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时11分,Denali Therapeutics Inc.股票出现波动,股价急速拉升5.08%。截至发稿,该股报22.95美元/股,成交量11.0322万股,换手率0.08%,振幅5.20%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为1.14%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502042311079617de40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502042311079617de40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4548","BK4535","DNLI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508256001","title":"Denali Therapeutics Inc.盘中异动 股价大跌5.02%报22.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508256001","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508256001?lang=zh_cn&edition=full","pubTime":"2025-02-04 01:07","pubTimestamp":1738602440,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日01时07分,Denali Therapeutics Inc.股票出现波动,股价快速跳水5.02%。截至发稿,该股报22.13美元/股,成交量23.4655万股,换手率0.16%,振幅3.00%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.62%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502040107209879855a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502040107209879855a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","LENZ","DNLI","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506451062","title":"高盛:维持Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506451062","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506451062?lang=zh_cn&edition=full","pubTime":"2025-01-28 23:33","pubTimestamp":1738078416,"startTime":"0","endTime":"0","summary":"高盛:维持Denali Therapeutics(DNLI.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至40.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/28233347883249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["DNLI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505789672","title":"Denali Therapeutics Inc.盘中异动 下午盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505789672","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505789672?lang=zh_cn&edition=full","pubTime":"2025-01-22 04:17","pubTimestamp":1737490642,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日04时17分,Denali Therapeutics Inc.股票出现异动,股价急速上涨5.02%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为1.86%。其相关个股中,Dogwood Therapeutics, Inc.、Camp4 Therapeutics Corporation、Channel Therapeutics Corporation涨幅较大,Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃,换手率分别为1295.07%、527.07%、190.74%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Revolution Medicines Inc C/Wts 17/12/2026 ,振幅分别为103.72%、96.32%、67.67%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122041723abb38f84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122041723abb38f84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DNLI","BK4548","LENZ","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503029647","title":"Denali Therapeutics Inc.盘中异动 早盘快速拉升5.12%报19.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503029647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503029647?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:30","pubTimestamp":1736951458,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时30分,Denali Therapeutics Inc.股票出现波动,股价急速上涨5.12%。截至发稿,该股报19.70美元/股,成交量5647股,换手率0.00%,振幅0.00%。Denali Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.00%。Denali Therapeutics Inc.公司简介:Denali Therapeutics Inc是一家生物技术公司,致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152230589604b38a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152230589604b38a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","DNLI","BK4139","LENZ","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.denalitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0454},{"period":"1month","weight":-0.1002},{"period":"3month","weight":-0.2034},{"period":"6month","weight":-0.0735},{"period":"1year","weight":0.1593},{"period":"ytd","weight":0.1151}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Denali Therapeutics Inc.于2013年10月在特拉华州注册成立。他们的目标是发现和开发可以战胜神经退行性疾病的治疗药物。神经退化代表了他们那个时代最重要的未得到满足的医疗需求之一,比如阿尔茨海默病,帕金森病疾病,肌萎缩性侧索硬化症或ALS,以及其他神经退化性疾病。这些疾病对患者和社会的负担是巨大的。他们相信现在正是他们利用强有力和雄心勃勃的努力来打败神经退化的正确时机。他们相信,他们可以在一个很少成功的领域取得了成就,因为他们拥有丰富的成功经验、热忱的科学家和药物开发者团队,他们专注的科学战略,以及他们专有的血脑屏障(BBB)平台输送技术。他们正在开发广泛的神经退行性疾病靶向治疗候选药物组合,并且最近开始了他们的第一个临床试验。他们于2015年5月开始运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.068767},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.02262},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.087803},{"month":4,"riseRate":0.555556,"avgChangeRate":0.007711},{"month":5,"riseRate":0.777778,"avgChangeRate":0.055944},{"month":6,"riseRate":0.666667,"avgChangeRate":0.078033},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.052711},{"month":8,"riseRate":0.666667,"avgChangeRate":0.063503},{"month":9,"riseRate":0.444444,"avgChangeRate":0.005049},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.045434},{"month":11,"riseRate":0.625,"avgChangeRate":0.13715},{"month":12,"riseRate":0.375,"avgChangeRate":0.011033}],"exchange":"NASDAQ","name":"Denali Therapeutics Inc.","nameEN":"Denali Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Denali Therapeutics Inc.(DNLI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Denali Therapeutics Inc.(DNLI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Denali Therapeutics Inc.,DNLI,Denali Therapeutics Inc.股票,Denali Therapeutics Inc.股票老虎,Denali Therapeutics Inc.股票老虎国际,Denali Therapeutics Inc.行情,Denali Therapeutics Inc.股票行情,Denali Therapeutics Inc.股价,Denali Therapeutics Inc.股市,Denali Therapeutics Inc.股票价格,Denali Therapeutics Inc.股票交易,Denali Therapeutics Inc.股票购买,Denali Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Denali Therapeutics Inc.(DNLI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Denali Therapeutics Inc.(DNLI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}